Literature DB >> 24418399

Association of RAGE gene polymorphism with vascular complications in Indian type 2 diabetes mellitus patients.

Ashok Kumar Tripathi1, Diwesh Chawla2, Savita Bansal3, Basu Dev Banerjee4, Sri Venkata Madhu5, Om Prakash Kalra6.   

Abstract

AIMS: The study was designed to evaluate the association of -374T/A and -429T/C polymorphism in the promoter region and Gly82Ser polymorphism in exon 3 region of RAGE gene with diabetic vascular complications in Indian population.
METHODS: We screened 603 subjects which includes 176 healthy controls, 140 type 2 diabetes mellitus (T2DM) subjects without any vascular complications (DM), 152 T2DM subjects with microvascular complications (DM-micro) and 135 T2DM subjects with macrovascular complications (DM-macro) for -374T/A, -429T/C and Gly82Ser polymorphisms of RAGE gene. DNA isolated from the enrolled subjects were genotyped by PCR-RFLP. Logistic regression analysis was used to evaluate the association of single nucleotide polymorphisms (SNPs).
RESULTS: The -429 T/C and Gly82Ser RAGE polymorphisms were found to be significantly associated with the development of macrovascular and microvascular complications, respectively, in T2DM subjects while -374A allele showed reduced risk towards the development of macrovascular complications. Further, -429T/C, -374T/A and Gly82Ser haplotype analysis revealed association of CTG haplotype with development of macrovascular complications while haplotype TAG was observed to be significantly protective towards development of macrovascular complications in T2DM subjects (OR=0.617, p=0.0202).
CONCLUSIONS: Our data indicates significant association of RAGE SNPs and haplotypes with vascular complications in North Indian T2DM subjects.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  RAGE gene Polymorphism; Type 2 diabetes mellitus; Vascular complications

Mesh:

Substances:

Year:  2013        PMID: 24418399     DOI: 10.1016/j.diabres.2013.12.004

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  7 in total

1.  Receptor for advanced glycation end products gene polymorphisms in cardiac syndrome X.

Authors:  Burak Önal; Deniz Özen; Bülent Demir; Ahmet G Akkan; Sibel Özyazgan
Journal:  Biomed Rep       Date:  2019-07-22

2.  Soluble receptor and gene polymorphism for AGE: relationship with obesity and cardiovascular risks.

Authors:  Mohamed Rowisha; Manal El-Batch; Thanaa El Shikh; Salwa El Melegy; Hany Aly
Journal:  Pediatr Res       Date:  2016-03-18       Impact factor: 3.756

3.  Polymorphisms of the receptor for advanced glycation end products as vasculopathy predictor in sickle cell disease.

Authors:  Nesma Ahmed Safwat; Mai Mohamed ELkhamisy; Soha Ezz AlArab Abdel-Wahab; Mohamed Tarif Hamza; Noha Hussein Boshnak; Mahmoud Adel Kenny
Journal:  Pediatr Res       Date:  2020-06-16       Impact factor: 3.756

4.  Association analysis of 374T/A (rs1800624) receptor for advanced glycation end-products (RAGE) gene polymorphism with diabetic retinopathy in Pakistani patients.

Authors:  Shazia Qayyum; Muhammad Afzal; Abdul Khaliq Naveed
Journal:  Pak J Med Sci       Date:  2021 May-Jun       Impact factor: 1.088

5.  The Association of -429T>C and -374T>A Polymorphisms in the RAGE Gene with Polycystic Ovary Syndrome.

Authors:  Jung-Hyun Park; Lan Li; Jin-Woo Choi; Kwang-Hyun Baek
Journal:  Int J Med Sci       Date:  2016-06-01       Impact factor: 3.738

6.  Genetic Variants of the Receptor for Advanced Glycation End-products in Susceptibility to Type 2 Diabetes Mellitus in Primary Hypertensive Patients.

Authors:  Hualing Yang; Yangyang Nie; Zhenyi Chen; Linyang Ye; Qingxiang Wang; Zhanxiang Wang
Journal:  Sci Rep       Date:  2017-12-08       Impact factor: 4.379

7.  Barriers to the early initiation of Insulin therapy among diabetic patients coming to diabetic clinics of tertiary care hospitals.

Authors:  Iqra Arshad; Sara Mohsin; Sana Iftikhar; Tahseen Kazmi; Luqman F Nagi
Journal:  Pak J Med Sci       Date:  2019 Jan-Feb       Impact factor: 1.088

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.